SecurityLRN / K12 Inc. (48273U102)
Chairman and CEODAVIS NATHANIEL A
Form 4 Count384
Form 8-K Count71
Form SC 13G/A Count39
Form 10-Q Count20

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to K12 Inc.


DateFormTitle
2018-06-11 8-K LRN / K12 Inc. K12 INC. 8-K (Current Report)
2018-05-16 8-K LRN / K12 Inc. K12 INC. 8-K (Current Report)
2018-05-14 SC 13D/A LRN / K12 Inc. / TCV VII LP - SC 13D/A (Activist Investment)
2018-05-14 SC 13D/A LRN / K12 Inc. / TCV VII LP - SC 13D/A (Activist Investment)
2018-04-30 SC 13D/A LRN / K12 Inc. / TCV VII LP - SC 13D/A (Activist Investment)
2018-04-30 SC 13D/A LRN / K12 Inc. / TCV VII LP - SC 13D/A (Activist Investment)
2018-04-25 10-Q LRN / K12 Inc. 10-Q (Quarterly Report)
2018-04-24 8-K LRN / K12 Inc. K12 INC. 8-K (Current Report)
2018-02-16 SC 13D/A LRN / K12 Inc. / TCV VII LP - SC 13D/A (Activist Investment)
2018-02-16 SC 13D/A LRN / K12 Inc. / TCV VII LP - SC 13D/A (Activist Investment)
2018-02-14 8-K LRN / K12 Inc. 8-K (Current Report)
2018-02-09 SC 13G/A LRN / K12 Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)
2018-02-09 SC 13G/A LRN / K12 Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)
2018-02-09 SC 13G/A LRN / K12 Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A (Passive Investment)
2018-02-09 SC 13G/A LRN / K12 Inc. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A (Passive Investment)
2018-01-26 10-Q LRN / K12 Inc. 10-Q (Quarterly Report)
2018-01-25 8-K LRN / K12 Inc. K12 INC. 8-K (Current Report)
2018-01-25 SC 13G/A LRN / K12 Inc. / BlackRock Inc. - 3G/A (Passive Investment)
2018-01-25 SC 13G/A LRN / K12 Inc. / BlackRock Inc. - 3G/A (Passive Investment)
2018-01-11 8-K LRN / K12 Inc. 8-K (Current Report)
2017-12-15 8-K LRN / K12 Inc. 8-K (Current Report)
2017-11-24 8-K LRN / K12 Inc. 8-K (Current Report)
2017-10-28 DEFA14A K12 DEFA14A
2017-10-28 DEF 14A K12 DEF 14A
2017-10-27 10-Q K12 10-Q (Quarterly Report)
2017-10-31 8-K K12 K12 INC. 8-K (Current Report/Significant Event)
2017-09-08 CT ORDER K12 RDER
2017-08-09 10-K K12 10-K (Annual Report)
2017-08-08 8-K K12 8-K (Current Report/Significant Event)
2017-08-08 8-K K12 K12 INC. 8-K (Current Report/Significant Event)
2017-07-12 8-K K12 8-K (Current Report/Significant Event)
2017-04-28 10-Q K12 10-Q (Quarterly Report)
2017-04-27 8-K K12 K12 INC. 8-K (Current Report/Significant Event)
2017-04-13 8-K K12 8-K (Current Report/Significant Event)
2017-03-22 S-8 POS K12 S-8 POS
2017-03-22 S-8 POS K12 S-8 POS
2017-03-22 S-8 POS K12 S-8 POS
2017-03-22 S-8 POS K12 S-8 POS
2017-02-10 SC 13G/A K12 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-10 SC 13G/A K12 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-10 SC 13G/A K12 SC 13G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-10 SC 13G/A K12 SC 13G/A (Passive Acquisition of More Than 5% of Shares)
2017-02-09 SC 13G K12 SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)
2017-02-09 SC 13G K12 SCHEDULE 13G (Passive Acquisition of More Than 5% of Shares)
2017-01-27 10-Q K12 10-Q (Quarterly Report)
2017-01-26 8-K K12 K12 INC. 8-K (Current Report/Significant Event)
2017-01-25 SC 13G/A K12 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-01-25 SC 13G/A K12 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-01-10 8-K K12 8-K (Current Report/Significant Event)
2016-12-16 8-K K12 8-K (Current Report/Significant Event)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 48273U102